Immunomedics awarded broad patent for anti-CD20 and anti-CD22 combination therapy (Globenewswire) - Jan 31, 2012 - Immunomedics announced the issuance of US patent 8,105,596, "Immunotherapy of B-cell malignancies using anti-CD22 antibodies"; This patent covers therapeutic compositions comprising any combination of conjugated or unconjugated anti-CD20 and anti-CD22 antibodies, which may be administered separately or concurrently; The patent provides coverage until 2018
Patent issuance • Hematological Malignancies • Non-Hodgkin's Lymphoma
|
|
Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the issuance of US patent 8,105,596, "Immunotherapy of B-cell malignancies using anti-CD22 antibodies."
This patent covers therapeutic compositions comprising any combination of conjugated or unconjugated anti-CD20 and anti-CD22 antibodies, which may be administered separately or concurrently. The therapeutic compositions are of use for treating diseases such as B-cell malignancies, non-Hodgkin's lymphoma, indolent and aggressive forms of B-cell lymphoma, and acute and chronic forms of lymphatic leukemias. The patent provides coverage until 2018.
Commenting on the patent award, Cynthia L. Sullivan, President and Chief Executive Officer remarked, "We are pleased to receive this important new patent. We have seen positive results in clinical trials combining our anti-CD22 antibody, epratuzumab, with the anti-CD20 antibody, rituximab. With the recent unencumbered return of the oncology indication for epratuzumab, new opportunities for licensing of epratuzumab and veltuzumab, our own anti-CD20 antibody, in combination for cancer therapy are available."
|